Evolution of Novel Non-Steroidal Anti-Inflammatory Drugs with Reduced Gastrointestinal Adverse Effects

ISSN: 1875-614X (Online)
ISSN: 1871-5230 (Print)

Volume 16, 3 Issues, 2017

Download PDF Flyer

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Claudiu T. Supuran
Neurofarba Department
University of Florence

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Evolution of Novel Non-Steroidal Anti-Inflammatory Drugs with Reduced Gastrointestinal Adverse Effects

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 8(3): 270-278.

Author(s): Umid Kumar Shrestha, Rakesh Kumar Jha and Bing Xia.

Affiliation: Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Donghu Road 169, Wuhan 430071, Hubei Province, P.R. of China.


Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used to relieve pain and symptoms of arthritis and soft tissue inflammation. The gastrointestinal (GI) adverse effects such as gastric and duodenal ulcers and their complications are the major limitations to the prescription of these drugs. As many as 25% of chronic NSAID users develop peptic ulcer disease among which 2%-4% bleed or perforate. Hence, the emphasis has always been on developing novel NSAIDs without GI toxicity. Selective cyclooxygenase (COX)-2 inhibitors (coxibs) elicit less clinically significant GI damage and bleeding than conventional NSAIDs, but there are concerns about the cardiovascular safety of these drugs. New treatment modalities such as Nitric Oxide (NO) releasing NSAIDs, dual COX/5-lipooxygenase (5-LOX) inhibitors and selective inhibition of terminal Prostaglandin synthases may be superior to coxibs in terms of reducing toxicity and increasing potency and efficacy. The advent of new mediators (lipoxins, Hydrogen Sulfide) may offer new key targets for safer NSAIDs. Several Phosphatidylcholine (PC)-NSAIDs, which were found to have increased analgesic and antiinflammatory activity with significantly less gastric and intestinal damage in animal models, are now in the advanced clinical trial. The R-enantiomers of NSAIDs, which may be helpful in chemoprevention of cancer and Alzheimers disease, generally exhibit greatly reduced GI toxicity. The evolution of these different novel NSAIDs may provide new modalities of anti-inflammatory therapies with greatly reduced GI toxicity.


Non-steroidal anti-inflammatory drug, gastrointestinal toxicity, COX-2 inhibitor, COX/5-LOX inhibitor, NO releasing NSAID.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 8
Issue Number: 3
First Page: 270
Last Page: 278
Page Count: 9
DOI: 10.2174/187152309789152011
Price: $58

Related Journals

Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science